The Medicines Company (MDCO) 25.44 $MDCO
The Medicines Company to Review ORBACTIV(TM)(oritavancin) Launch Readiness on Tuesday, September 16, 2014
Business Wire - 30 mins ago
The Medicines Company (NASDAQ:MDCO) has scheduled a conference call for Tuesday, September 16 at 7:30 a.m. Eastern Time to discuss plans for launching ORBACTIV(TM) (oritavancin) for injection, the first and only single-dose, FDA-approved antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive pathogens.
The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Business Wire - Wed Aug 27, 12:12PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014.
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.
Sell These 5 Toxic Stocks Before It's Too Late
at The Street - Fri Aug 15, 6:56AM CDT
It's time to unload these toxic stocks from your portfolio.
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
Medicines Co Earnings In Retrospect: Down 1.7% in the Last 19 Days (MDCO)
Comtex SmarTrend(R) - Mon Aug 11, 12:09PM CDT
Two weeks ago on July 23rd, 2014 Medicines Co (NASDAQ:MDCO) reported earnings and analysts, on average, expected earnings of $0.39 on sales of $184.1 million. The company actually reported EPS of $0.31 on sales of $183.8 million, missing EPS estimates by $0.08 and matching revenue estimates. Shares of Medicines Co have slipped from $24.87 to $24.45, representing a loss of 1.7%, since the company reported earnings 19 days ago.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
The Medicines Company's Orbactiv Approved on Solid SOLO Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 5:10PM CDT
Great news came in The Medicines Company's (MDCO) way when the FDA approved the company's antibiotic Orbactiv.
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
FDA Approves The Medicines Company's ORBACTIV(TM) (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
Business Wire - Wed Aug 06, 7:31PM CDT
--ORBACTIV(TM)U.S. Launch Expected in 2H/2014
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
10.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Mon Aug 04, 10:07AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on July 17th, 2014 at $25.89. In approximately 3 weeks, Medicines Co has returned 10.27% as of today's recent price of $23.23.
The Medicines Company to Host Infectious Disease Care Investor and Analyst Meeting on September 24, 2014
Business Wire - Mon Aug 04, 7:33AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled an Infectious Disease Care Investor and Analyst meeting for Wednesday, September 24, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company's emerging core business in Infectious Disease Care.
Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:30PM CDT
Incyte (INCY) announced disappointing top-line results from the RELIEF study on Jakafi in the PV indication.
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.
Amicus Therapeutics (FOLD) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 7% on the day.
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:20AM CDT
The Medicines Co. (MDCO) has an important regulatory event coming up with the FDA expected to respond on the approval status of Orbactiv by Aug 6.
Medicines (MDCO) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:01AM CDT
Medicines (MDCO) is Oversold: Can It Recover?
The Medicines Company to Review ORBACTIV(TM)(oritavancin) Launch Readiness on Tuesday, September 16, 2014
Business Wire - 30 mins ago
The Medicines Company (NASDAQ:MDCO) has scheduled a conference call for Tuesday, September 16 at 7:30 a.m. Eastern Time to discuss plans for launching ORBACTIV(TM) (oritavancin) for injection, the first and only single-dose, FDA-approved antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive pathogens.
The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Business Wire - Wed Aug 27, 12:12PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014.
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.
Sell These 5 Toxic Stocks Before It's Too Late
at The Street - Fri Aug 15, 6:56AM CDT
It's time to unload these toxic stocks from your portfolio.
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
Medicines Co Earnings In Retrospect: Down 1.7% in the Last 19 Days (MDCO)
Comtex SmarTrend(R) - Mon Aug 11, 12:09PM CDT
Two weeks ago on July 23rd, 2014 Medicines Co (NASDAQ:MDCO) reported earnings and analysts, on average, expected earnings of $0.39 on sales of $184.1 million. The company actually reported EPS of $0.31 on sales of $183.8 million, missing EPS estimates by $0.08 and matching revenue estimates. Shares of Medicines Co have slipped from $24.87 to $24.45, representing a loss of 1.7%, since the company reported earnings 19 days ago.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
The Medicines Company's Orbactiv Approved on Solid SOLO Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 5:10PM CDT
Great news came in The Medicines Company's (MDCO) way when the FDA approved the company's antibiotic Orbactiv.
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
FDA Approves The Medicines Company's ORBACTIV(TM) (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
Business Wire - Wed Aug 06, 7:31PM CDT
--ORBACTIV(TM)U.S. Launch Expected in 2H/2014
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
10.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Mon Aug 04, 10:07AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on July 17th, 2014 at $25.89. In approximately 3 weeks, Medicines Co has returned 10.27% as of today's recent price of $23.23.
The Medicines Company to Host Infectious Disease Care Investor and Analyst Meeting on September 24, 2014
Business Wire - Mon Aug 04, 7:33AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled an Infectious Disease Care Investor and Analyst meeting for Wednesday, September 24, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company's emerging core business in Infectious Disease Care.
Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:30PM CDT
Incyte (INCY) announced disappointing top-line results from the RELIEF study on Jakafi in the PV indication.
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:50AM CDT
Gilead (GILD) blew away estimates on strong Sovaldi sales.
Amicus Therapeutics (FOLD) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 7% on the day.
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:20AM CDT
The Medicines Co. (MDCO) has an important regulatory event coming up with the FDA expected to respond on the approval status of Orbactiv by Aug 6.
Medicines (MDCO) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:01AM CDT
Medicines (MDCO) is Oversold: Can It Recover?
